Targeting BCMA in Multiple Myeloma

[21] Kyle RA(2019)Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study Blood Cancer J 9 37-27

[22] Gertz MA(2020)DREAMM-6: safety, tolerability and clinical activity of belantamab mafodotin (belamaf) in combination with bortezomib/dexamethasone (BorDex) in relapsed/refractory multiple myeloma (RRMM) Blood 136 19-296

[23] Goldschmidt H(2020)Phase 1, First-in-Human Study of MEDI2228, a BCMA-targeted ADC in patients with relapsed/refractory multiple myeloma Blood 136 26-38

[24] Lokhorst HM(2015)Bispecific T-cell engagers for cancer immunotherapy Immunol Cell Biol 93 290-2463

[25] Mai EK(2018)Redirecting T cells to hematological malignancies with bispecific antibodies Blood 131 30-5150

[26] van der Holt B(2014)Controlled Fab-arm exchange for the generation of stable bispecific IgG1 Nat Protoc 9 2450-973

[27] Blau IW(2013)Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange Proc Natl Acad Sci U S A 110 5145-783

[28] Zweegman S(2013)Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches MAbs 5 962-9

[29] Weisel KC(2020)Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma J Clin Oncol 38 775-410

[30] Vellenga E(2016)Preclinical evaluation of a potent anti-BCMA CD3 bispecific molecule for the treatment of multiple myeloma Blood 128 383-4549

[21] Kyle RA(2019)Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study Blood Cancer J 9 37-27

[22] Gertz MA(2020)DREAMM-6: safety, tolerability and clinical activity of belantamab mafodotin (belamaf) in combination with bortezomib/dexamethasone (BorDex) in relapsed/refractory multiple myeloma (RRMM) Blood 136 19-296

[23] Goldschmidt H(2020)Phase 1, First-in-Human Study of MEDI2228, a BCMA-targeted ADC in patients with relapsed/refractory multiple myeloma Blood 136 26-38

[24] Lokhorst HM(2015)Bispecific T-cell engagers for cancer immunotherapy Immunol Cell Biol 93 290-2463

[25] Mai EK(2018)Redirecting T cells to hematological malignancies with bispecific antibodies Blood 131 30-5150

[26] van der Holt B(2014)Controlled Fab-arm exchange for the generation of stable bispecific IgG1 Nat Protoc 9 2450-973

[27] Blau IW(2013)Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange Proc Natl Acad Sci U S A 110 5145-783

[28] Zweegman S(2013)Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches MAbs 5 962-9

[29] Weisel KC(2020)Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma J Clin Oncol 38 775-410

[30] Vellenga E(2016)Preclinical evaluation of a potent anti-BCMA CD3 bispecific molecule for the treatment of multiple myeloma Blood 128 383-4549